Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
Level 5 - mechanism / opinion, no new human data
Narrative comparative review of pharmacology and clinical research without systematic review methodology described in the abstract.
PubMed 38301886 · doi:10.1016/j.bpsc.2024.01.007
What was done
The authors conducted a comparative review evaluating clinical research on five serotonergic (5-HT2A agonist) psychedelics: psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and mescaline. They reviewed their mechanisms of action, pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profiles.
What was found
The abstract reports no quantitative data or effect sizes. Qualitatively, the authors noted no differences in psychedelic effects among the compounds beyond effect duration. Therapeutic evidence for clinical indications remains scarce, with the exception of psilocybin for depression, leaving it unclear whether distinct receptor binding profiles affect therapeutic potential.
Why it matters
This review highlights that current evidence differentiates classical psychedelics primarily by duration of effect rather than therapeutic profiles, pointing to a need for head-to-head comparative research.
Limits
The abstract does not report quantitative outcomes, systematic search criteria, or the number of studies reviewed. High-quality clinical efficacy evidence across most of these compounds remains scarce.